度伐利尤单抗联合或不联合替西木单抗治疗持续性或复发性子宫内膜癌或子宫内膜癌肉瘤:一项随机开放标签2期研究
这项单中心随机开放标签2期研究将82例子宫内膜癌患者分配至度伐利尤单抗1500 mg组或度伐利尤单抗1500 mg联合替西木单抗75 mg每4周组,主要终点为总缓解率(ORR)和24周无进展生存期(PFS)。度伐利尤单抗组ORR为10.8%(单侧90% CI:4.8-100%),联合组ORR为5.3%(单侧90% CI:1.4-100%),未达到主要终点,未发现新的安全性信号。
要点
- 在以错配修复功能完整为主的子宫内膜癌患者中,单药和联合免疫检查点抑制的缓解有限。
- 度伐利尤单抗组ORR为10.8%,联合替西木单抗组ORR为5.3%,未达到预设疗效阈值。
- 因ORR主要终点未达到,按方案规定未将24周PFS与历史对照进行比较。
核心结论
- 在以错配修复功能完整为主的子宫内膜癌患者中,单药和联合免疫检查点抑制的缓解有限,未达到预设的进一步评估疗效阈值。
- 需要更深入理解错配修复功能完整子宫内膜癌对免疫治疗耐药的潜在机制,以开发新的治疗策略。
研究设计与样本
- 单中心、随机、开放标签、2期研究,比较度伐利尤单抗1500 mg(第1组)与度伐利尤单抗1500 mg联合替西木单抗75 mg每4周(第2组)治疗子宫内膜癌患者。
- 主要终点为总缓解率(ORR)和24周无进展生存期(PFS)。
- 患者按错配修复(MMR)状态和癌肉瘤组织学分层。
- 采用Simon两阶段极小极大设计,确定每组40例患者可提供90%把握度和10%的I类错误率。
- 共入组82例患者;77例可评估毒性(第1组38例,第2组39例),75例可评估疗效(第1组37例,第2组38例)。
主要发现
- 第1组ORR为10.8%(单侧90% CI:4.8-100%);第2组ORR为5.3%(单侧90% CI:1.4-100%)。
- 因ORR主要终点未达到,按方案规定未将24周PFS与历史对照进行比较。
- 未发现新的安全性信号。
临床怎么用
- 原文未据此给出推荐。
局限性
- 因ORR主要终点未达到,按方案规定未将24周PFS与历史对照进行比较。
- 需要更深入理解错配修复功能完整子宫内膜癌对免疫治疗耐药的潜在机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Our understanding of the biologic heterogeneity of endometrial cancer has improved, but which patients benefit from single-agent versus combination immune checkpoint blockade remains unclear. METHODS: We conducted a single-center, randomized, open-label, phase 2 study of durvalumab 1500 mg (Arm 1) versus durvalumab 1500 mg plus tremelimumab 75 mg every 4 weeks (Arm 2) in patients with endometrial carcinoma. The primary endpoints were overall response rate (ORR) and progression-free survival (PFS) at 24 weeks. Patients were stratified by mismatch repair (MMR) status and carcinosarcoma histology. Using a Simon two-stage minimax design, we determined 40 patients per arm would provide 90% power and Type 1 error of 10%. RESULTS: Eighty-two patients were enrolled; 77 were evaluable for toxicity (Arm 1: 38, Arm 2: 39) and 75 evaluable for efficacy (Arm 1: 37, Arm 2: 38). Patient were stratified by MMR status (Arm 1: 5, Arm 2: 4 were MMR-deficient). The ORR in Arm 1 was 10.8% (one-sided 90% CI: 4.8-100%); the ORR in Arm 2 was 5.3% (one-sided 90% CI: 1.4-100%). Since the primary endpoint of ORR was not met, 24-week PFS was not compared to historical controls per protocol specification. No new safety signals were identified. CONCLUSIONS: In these patients with predominantly MMR-proficient endometrial cancer, there was limited response with single-agent and combined immune checkpoint blockade. The pre-specified efficacy thresholds were not met for further evaluation. A deeper understanding of potential mechanisms of resistance to immunotherapy in MMR-proficient endometrial cancer is needed for the development of novel therapeutic approaches.
引用
- Rubinstein MM, Doria ER, Konner J, et al. Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study. Gynecol Oncol. 2022. PMID: 36512912. doi:10.1016/j.ygyno.2022.11.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。